EMPA-REG - the "diuretic hypothesis"

J Diabetes Complications. Jan-Feb 2016;30(1):3-4. doi: 10.1016/j.jdiacomp.2015.10.012. Epub 2015 Oct 21.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use
  • Arrhythmias, Cardiac / complications
  • Arrhythmias, Cardiac / epidemiology
  • Arrhythmias, Cardiac / prevention & control
  • Arrhythmias, Cardiac / therapy
  • Benzhydryl Compounds / therapeutic use*
  • Controlled Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetic Cardiomyopathies / epidemiology
  • Diabetic Cardiomyopathies / prevention & control*
  • Diabetic Cardiomyopathies / therapy
  • Diuretics / therapeutic use*
  • Glucosides / therapeutic use*
  • Heart Failure / complications
  • Heart Failure / epidemiology
  • Heart Failure / prevention & control*
  • Heart Failure / therapy
  • Hospitalization
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Membrane Transport Modulators / therapeutic use
  • Models, Biological*
  • Risk
  • Sodium-Glucose Transporter 2 / metabolism
  • Sodium-Glucose Transporter 2 Inhibitors

Substances

  • Anti-Arrhythmia Agents
  • Benzhydryl Compounds
  • Diuretics
  • Glucosides
  • Hypoglycemic Agents
  • Membrane Transport Modulators
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin